Vaxcyte, Inc. PCVX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s stock-based comp?
- Vaxcyte, Inc. (PCVX) reported stock-based comp of $37.96M in Q1 2026.
- How has Vaxcyte, Inc.'s stock-based comp changed year-over-year?
- Vaxcyte, Inc.'s stock-based comp increased by 24.0% year-over-year, from $30.62M to $37.96M.
- What is the long-term trend for Vaxcyte, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s stock-based comp has grown at a 89.7% compound annual growth rate (CAGR), from $10.73M to $138.85M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.